Enzyme replacement therapy and renal function in 201 patients with Fabry disease - PubMed (original) (raw)
Affiliations
- PMID: 16939062
Enzyme replacement therapy and renal function in 201 patients with Fabry disease
A Schwarting et al. Clin Nephrol. 2006 Aug.
Abstract
Aim: Fabry disease is a rare lysosomal storage disorder caused by deficient activity of alpha-galactosidase A, resulting in progressive cellular accumulation of glycolipids, which may ultimately result in endstage renal disease. We examined the effects of enzyme replacement therapy (ERT) with Agalsidase-alpha on renal function using data from a large international database, the Fabry Outcome Survey (FOS).
Methods: This analysis was based on 1,040 serum creatinine measurements in 201 patients with Fabry disease, aged 20 - 60 years, with serum creatinine concentrations of less than 2 mg/dl and duration of ERT of up to 4.7 years. Both pretreatment and treatment data were used to examine independent predictors of changes in serum creatinine. In a second approach longitudinal serum creatinine measurements from 1 year before treatment, at baseline and 1 and 2 years after the start of treatment were analyzed in 20 patients with chronic kidney disease (CKD) Stage 2 and 3.
Results: We found an independent negative association between serum creatinine and time on Agalsidase-alpha treatment (p < 0.05). Renal function declined significantly (p < 0.05) in the year before treatment. After 1 year of treatment, however, the decline in estimated glomerular filtration rate had been halted, and renal function was preserved for up to 2 years.
Conclusions: In conclusion, ERT with Agalsidase-alpha is associated with decrease of serum creatinine and may prevent the deterioration of renal function in patients with Fabry disease.
Similar articles
- Fabry disease: overall effects of agalsidase alfa treatment.
Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Beck M, et al. Eur J Clin Invest. 2004 Dec;34(12):838-44. doi: 10.1111/j.1365-2362.2004.01424.x. Eur J Clin Invest. 2004. PMID: 15606727 Clinical Trial. - Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R, Feriozzi S, Pisani A, Cioni A, Comotti C, Cossu M, Foschi A, Giudicissi A, Gotti E, Lozupone VA, Marchini F, Martinelli F, Bianco F, Panichi V, Procaccini DA, Ragazzoni E, Serra A, Soliani F, Spinelli L, Torti G, Veroux M, Cianciaruso B, Cagnoli L. Mignani R, et al. Nephrol Dial Transplant. 2008 May;23(5):1628-35. doi: 10.1093/ndt/gfm813. Epub 2007 Dec 5. Nephrol Dial Transplant. 2008. PMID: 18057066 - Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
Thofehrn S, Netto C, Cecchin C, Burin M, Matte U, Brustolin S, Nunes AC, Coelho J, Tsao M, Jardim L, Giugliani R, Barros EJ. Thofehrn S, et al. Ren Fail. 2009;31(9):773-8. doi: 10.3109/08860220903150296. Ren Fail. 2009. PMID: 19925283 Clinical Trial. - Agalsidase alfa slows the decline in renal function in patients with Fabry disease.
Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M; International Fabry Outcome Survey Investigators. Feriozzi S, et al. Am J Nephrol. 2009;29(5):353-61. doi: 10.1159/000168482. Epub 2008 Oct 31. Am J Nephrol. 2009. PMID: 18974635 Review. - Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
Cybulla M, Kurschat C, West M, Nicholls K, Torras J, Sunder-Plassmann G, Feriozzi S. Cybulla M, et al. J Nephrol. 2013 Jul-Aug;26(4):645-51. doi: 10.5301/jn.5000214. Epub 2012 Sep 19. J Nephrol. 2013. PMID: 23023720 Review.
Cited by
- Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.
El Dib R, Gomaa H, Ortiz A, Politei J, Kapoor A, Barreto F. El Dib R, et al. PLoS One. 2017 Mar 15;12(3):e0173358. doi: 10.1371/journal.pone.0173358. eCollection 2017. PLoS One. 2017. PMID: 28296917 Free PMC article. - Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A).
Lin HY, Liu HC, Huang YH, Liao HC, Hsu TR, Shen CI, Li ST, Li CF, Lee LH, Lee PC, Huang CK, Chiang CC, Lin CY, Lin SP, Niu DM. Lin HY, et al. BMJ Open. 2013 Jul 16;3(7):e003146. doi: 10.1136/bmjopen-2013-003146. Print 2013. BMJ Open. 2013. PMID: 23864212 Free PMC article. - Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy.
Ramaswami U, Pintos-Morell G, Kampmann C, Nicholls K, Niu DM, Reisin R, West ML, Anagnostopoulou C, Botha J, Jazukeviciene D, Schenk J, Hughes DA, Giugliani R. Ramaswami U, et al. Mol Genet Metab Rep. 2025 Apr 11;43:101215. doi: 10.1016/j.ymgmr.2025.101215. eCollection 2025 Jun. Mol Genet Metab Rep. 2025. PMID: 40276560 Free PMC article. - [Effect of enzyme replacement therapy (ERT) on renal function of patients with Fabry's disease].
Thomaidis T, Relle M, Reinke J, Beck M, Schwarting A. Thomaidis T, et al. Med Klin (Munich). 2009 Sep 15;104(9):699-703. doi: 10.1007/s00063-009-1152-1. Epub 2009 Sep 23. Med Klin (Munich). 2009. PMID: 19779674 Review. German. - The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.
Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, Nowak A, Oliveira JP, Pieroni M, Viana-Baptista M, Wanner C, Spada M. Germain DP, et al. Mol Genet Metab Rep. 2019 Feb 6;19:100454. doi: 10.1016/j.ymgmr.2019.100454. eCollection 2019 Jun. Mol Genet Metab Rep. 2019. PMID: 30775256 Free PMC article. Review.